ARWAR: A network approach for predicting Adverse Drug Reactions

Computers in Biology and Medicine

Volumn 68, Issue , 2016, Pages 101-108

  Rahmani, Hossein ^a,b   Weiss, Gerhard ^b   Méndez Lucio, Oscar ^c   Bender, Andreas ^c  

^a IRAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Iran)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adverse Drug Reactions; Graph augmentation; Human Drug Network; Multi label classification; Network approach; Random Walk with Restarts; Side effects

Indexed keywords

CLASSIFICATION (OF INFORMATION); FORECASTING; RANDOM PROCESSES;

ADVERSE DRUG REACTIONS; GRAPH AUGMENTATION; MULTI LABEL CLASSIFICATION; RANDOM WALK; SIDE EFFECT;

DRUG INTERACTIONS;

4 AMINOBUTYRIC ACID;

ADVERSE DRUG REACTION; ARTICLE; AUGMENTED RANDOM WALK WITH RESTART; CHEMICAL STRUCTURE; COMPUTER PROGRAM; EPITHELIUM CELL; GENE ONTOLOGY; HUMAN; K NEAREST NEIGHBOR; MACHINE LEARNING; PAIN RECEPTOR; PREDICTION; PRIORITY JOURNAL; SUPPORT VECTOR MACHINE; ANIMAL; DRUG DEVELOPMENT; DRUG INTERACTION; FACTUAL DATABASE; INFORMATION SERVICE; PROCEDURES;

ANIMALS; DATABASES, FACTUAL; DRUG DISCOVERY; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFORMATION SERVICES;

EID: 84949235014     PISSN: 00104825     EISSN: 18790534     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2015.11.005     Document Type: Article

References (68)

1. Myers S., Baker A. Drug discovery-an operating model for a new era. Nat. Biotechnol. 2001, 19(8):727-730. 10.1038/90765.
2. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation. new estimates of drug development costs. J. Health Econ. 2003, 22(2):151-185. 10.1016/S0167-6296(02)00126-1.
3. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. a meta-analysis of prospective studies. J. Am. Med. Assoc. 1998, 279(15):1200-1205. 10.1001/jama.279.15.1200.
4. Giacomini K.M., Krauss R.M., Roden D.M., Eichelbaum M., Hayden M.R., Nakamura Y. When good drugs go bad. Nature 2007, 446(7139):975-977. 10.1038/446975a.
5. Hammann F., Gutmann H., Vogt N., Helma C., Drewe J. Prediction of adverse drug reactions using decision tree modeling. Clin. Pharmacol. Ther. 2010, 88(1):52-59. 10.1038/clpt.2009.248.
6. Bender A., Scheiber J., Glick M., Davies J.W., Azzaoui K., Hamon J., Urban L., Whitebread S., Jenkins J.L. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007, 2(6):861-873. 10.1002/cmdc.200700026.
7. Xie L., Li J., Xie L., Bourne P.E. Drug discovery using chemical systems biology. identification of the protein-ligand binding network to explain the side effects of cetp inhibitors. PLoS Comput. Biol. 2009, 5(5):e1000387. 10.1371/journal.pcbi.1000387.
8. Scheiber J., Jenkins J.L., Sukuru S.C.K., Bender A., Mikhailov D., Milik M., Azzaoui K., Whitebread S., Hamon J., Urban L., Glick M., Davies J.W. Mapping adverse drug reactions in chemical space. J. Med. Chem. 2009, 52(9):3103-3107. pMID: 19378990. 10.1021/jm801546k.
9. Campillos M., Kuhn M., Gavin A.-C., Jensen L.J., Bork P. Drug target identification using side-effect similarity. Science 2008, 321(5886):263-266. 10.1126/science.1158140.
10. Yamanishi Y., Pauwels E., Kotera M. Drug side-effect prediction based on the integration of chemical and biological spaces. J. Chem. Inf. Model. 2012, 52(12):3284-3292. 10.1021/ci2005548.
11. Atias N., Sharan R. An algorithmic framework for predicting side effects of drugs. J. Comput. Biol. 2011, 18(3):207-218. 10.1089/cmb.2010.0255.
12. Pauwels E., Stoven V., Yamanishi Y. Predicting drug side-effect profiles. a chemical fragment-based approach. BMC Bioinform. 2011, 12:169.
13. L.-C. Huang, X. Wu, J. Chen, Predicting adverse side effects of drugs, BMC Genomics 12 (5), 2011. doi:10.1186/1471-2164-12-S5-S11.
14. M. Fukuzaki, M. Seki, H. Kashima, J. Sese, Side effect prediction using cooperative pathways, in: Proceedings of the 2009 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2009, Washington, DC, USA, November 1-4, 2009, IEEE Computer Society, 2009, pp. 142-147. doi:10.1109/BIBM.2009.26.
15. Pouliot Y., Chiang A., Butte A. Predicting adverse drug reactions using publicly available pubchem bioassay data. Clin. Pharmacol. Ther. 2011, 90(1):90-99. 10.1038/clpt.2011.81.
16. Cruz-Monteagudo M., Gonzalez-Díaz H., Uriarte E. Simple stochastic fingerprints towards mathematical modeling in biology and medicine 2. Unifying Markov model for drugs side effects. Bull. Math. Biol. 2006, 68(7):1527-1554. 10.1007/s11538-005-9013-4.
17. Cook D.J., Holder L.B. Mining Graph Data 2006, John Wiley & Sons.
18. K. Goh, M. Cusick, D. Valle, B. Childs, M. Vidal, A. Barabási, The human disease network, Proc. Natl. Acad. Sci. 104 (21) (2007) 8685-8690. doi:10.1073/pnas.0701361104.
19. van Driel M.A., Bruggeman J., Vriend G., Brunner H.G., Leunissen J.A. A text-mining analysis of the human phenome. Eur. J. Human Genet.: EJHG 2006, 14(5):535-542. 10.1038/sj.ejhg.5201585.
20. Linghu B., Snitkin E., Hu Z., Xia Y., DeLisi C. Genome-wide prioritization of disease genes and identification of disease-disease associations from an integrated human functional linkage network. Genome Biol. 2009, 10(9):R91. 10.1186/gb-2009-10-9-r91.
21. Zhang M., Zhu C., Jacomy A., Lu L.J., Jegga A.G. The orphan disease networks. Am. J. Hum. Genet. 2011, 88(6):755-766. http://www.sciencedirect.com/science/article/pii/S0002929711001996.
22. S. Vilar, N.P. Tatonetti, G. Hripcsak, 3d pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance, Sci. Rep. 5, 2015. doi:10.1038/srep08809.
23. Luo H., Chen J., Shi L., Mikailov M., Zhu H., Wang K., He L., Yang L. DRAR-CPI. a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 2011, 39:492-498. (Web-Server-Issue). 10.1093/nar/gkr299.
24. H. Rahmani, H. Blockeel, A. Bender, Using a human drug network for generating novel hypotheses about drugs, Intell. Data Anal. 20 (1), 2015. URL . https://lirias.kuleuven.be/handle/123456789/474336.
25. Yildirim M.A., Goh K.-I., Cusick M.E., Barabási A.-L., Vidal M. Drug-target network. Nat. Biotechnol. 2007, 25(10):1119-1126. 10.1038/nbt1338.
26. Park K., Kim D. Drug-drug relationship based on target information. application to drug target identification. BMC Syst. Biol. 2011, 5(Suppl (2)):S12. 10.1186/1752-0509-5-S2-S12.
27. Brown R.D., Martin Y.C. The information content of 2D and 3D structural descriptors relevant to ligand-receptor binding. J. Chem. Inf. Comput. Sci. 1997, 37(1):1-9. 10.1021/ci960373c.
28. Hagadone T.R. Molecular substructure similarity searching. efficient retrieval in two-dimensional structure databases. J. Chem. Inf. Model. 1992, 32(5):515-521. http://pubs3.acs.org/acs/journals/doilookup?in_doi=10.1021/ci00009a019.
29. Kearsley S.K., Sallamack S., Fluder E.M., Andose J.D., Mosley R.T., Sheridan R.P. Chemical similarity using physiochemical property descriptors. J. Chem. Inf. Model. 1996, 36(1):118-127. 10.1021/ci950274j.
30. Schwikowski B., Uetz P., Fields S. A network of protein-protein interactions in yeast. Nat. Biotechnol. 2000, 18(12):1257-1261.
31. H. Rahmani, H. Blockeel, A. Bender, Predicting the functions of proteins in protein-protein interaction networks from global information, in: JMLR: Workshop and Conference Proceedings, 2010, pp. 82-97.
32. H. Rahmani, H. Blockeel, A. Bender, Collaboration-based function prediction in protein-protein interaction networks, in: J. Gama, E. Bradley, J. Hollmén (Eds.), IDA, Lecture Notes in Computer Science, vol. 7014, Springer, 2011, pp. 318-327.
33. R. Sharan, I. Ulitsky, R. Shamir, Network-based prediction of protein function, Mol. Syst. Biol. 3 (1), 2007. doi:10.1038/msb4100129.
34. Brouwers L., Iskar M., Zeller G., van Noort V., Bork P. Network neighbors of drug targets contribute to drug side-effect similarity. PLoS ONE 2011, 6(7):e22187. 10.1371/journal.pone.0022187.
35. Huang L.-C., Wu X., Chen J.Y. Predicting adverse drug reaction profiles by integrating protein interaction networks with drug structures. Proteomics 2013, 13(2):313-324. 10.1002/pmic.201200337.
36. Liu M., Wu Y., Chen Y., Sun J., Zhao Z., Chen X.-w., Matheny M.E., Xu H. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J. Am. Med. Inform. Assoc. 2012, 19(e1):e28-e35. 10.1136/amiajnl-2011-000699.
37. Bhagat S., Cormode G., Muthukrishnan S. Node classification in social networks,. In Social Network Data Analytics 2011, 115-148. Springer, US.
38. Zhang M., Zhou Z. A review on multi-label learning algorithms. IEEE Trans. Knowl. Data Eng. 2013, 99:1. 10.1109/TKDE.2013.39.
39. Cover T., Hart P. Nearest neighbor pattern classification, IEEE Trans. Inf. Theory 1967, 13(1):21-27.
40. J. Goldberger, S.T. Roweis, G.E. Hinton, R. Salakhutdinov, Neighbourhood components analysis, in: Advances in Neural Information Processing Systems 17, NIPS 2004, Vancouver, British Columbia, Canada, December 13-18, 2004, pp. 513-520. URL. http://papers.nips.cc/paper/2566-neighbourhood-components-analysis.
41. Weinberger K.Q., Saul L.K. Distance metric learning for large margin nearest neighbor classification. J. Mach. Learn. Res. 2009, 10:207-244.
42. D. Tran, A. Sorokin, Human activity recognition with metric learning, in: D.A. Forsyth, P.H.S. Torr, A. Zisserman (Eds.), Proceedings of the 10th European Conference on Computer Vision - ECCV 2008, Marseille, France, October 12-18, 2008, Lecture Notes in Computer Science, Part I, vol. 5302, Springer, 2008, pp. 548-561. doi:10.1007/978-3-540-88682-2_42.
43. L. Lovász, Random walks on graphs: a survey, in: D. Miklós, V.T. Sós, T. Szonyi (Eds.), Combinatorics, Paul Erdos is Eighty, vol. 2, János Bolyai Mathematical Society, Budapest, 1996, pp. 353-398.
44. Wishart D.S., Knox C., Guo A., Cheng D., Shrivastava S., Tzur D., Gautam B., Hassanali M. Drugbank. a knowledge base for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36:901-906. (Database-Issue).
45. M. Kuhn, M. Campillos, I. Letunic, L.J. Jensen, P. Bork, A side effect resource to capture phenotypic effects of drugs, Mol. Syst. Biol. 6 (1), 2010. doi:10.1038/msb.2009.98.
46. H. Rahmani, List of Drugs With Their Associated Target Proteins. https://www.dropbox.com/s/q201zyznm0y049q/drugTargetList.html?dl=0.
47. H. Rahmani, List of Drugs With Their Associated Side Effects. https://www.dropbox.com/s/kunj09s6cgvfq0y/drugSideEffectList.html?dl=0.
48. Rahmani H., Blockeel H., Bender A. Using a human disease network for augmenting prior knowledge about diseases. Intell. Data Anal. 2015, 19(4):897-916. 10.3233/IDA-150750.
49. Milenkovic T., Memisevic V., Ganesan A.K., Przulj N. Systems-level cancer gene identification from protein interaction network topology applied to melanogenesis-related functional genomics data. J. R. Soc. Interface/R. Soc. 2010, 7(44):423-437. 10.1098/rsif.2009.0192.
50. S. Peri, J.D. Navarro, T.Z. Kristiansen, R. Amanchy, V. Surendranath, B. Muthusamy, T.K. Gandhi, K.N. Chandrika, N. Deshpande, S. Suresh, B.P. Rashmi, K. Shanker, N. Padma, V. Niranjan, H.C. Harsha, N. Talreja, B.M. Vrushabendra, M.A. Ramya, A.J. Yatish, M. Joy, H.N. Shivashankar, M.P. Kavitha, M. Menezes, D.R. Choudhury, N. Ghosh, R. Saravana, S. Chandran, S. Mohan, C.K. Jonnalagadda, C.K. Prasad, C. Kumar-Sinha, K.S. Deshpande, A. Pandey, Human protein reference database as a discovery resource for proteomics, Nucleic Acids, 2004. (Database issue). http://view.ncbi.nlm.nih.gov/pubmed/14681466.
51. Stark C., Breitkreutz B.-J., Reguly T., Boucher L., Breitkreutz A., Tyers M. Biogrid. a general repository for interaction datasets. Nucleic Acids Res. 2006, 34:535-539. (Database-Issue).
52. Radivojac P., Peng K., Clark W.T., Peters B.J., Mohan A., Boyle S.M., Mooney S.D. An integrated approach to inferring gene-disease associations in humans. Proteins 2008, 72(3):1030-1037. 10.1002/prot.21989.
53. Cline M.S., Smoot M., Cerami E., Kuchinsky A., Landys N., Workman C., Christmas R., Avila-Campilo I., Creech M., Gross B., Hanspers K., Isserlin R., Kelley R., Killcoyne S., Lotia S., Maere S., Morris J., Ono K., Pavlovic V., Pico A.R., Vailaya A., Wang P.-L., Adler A., Conklin B.R., Hood L., Kuiper M., Sander C., Schmulevich I., Schwikowski B., Warner G.J., Ideker T., Bader G.D. Integration of biological networks and gene expression data using Cytoscape. Nat. Protocols 2007, 2(10):2366-2382. 10.1038/nprot.2007.324.
54. H. Rahmani, Human Drug Network. http://www.liacs.nl/~hrahmani/HDN/HDN-HRahmani-CytoFile.txt.
55. Anthony P., Trevor J., Walter M., Way L. Sedative-Hypnotic Drugs in Basic and Clinical Pharmacology, 12e 1972, The McGraw-Hill Companies, New York, NY, (Chapter 22).
56. Davis M.I., Hunt J.P., Herrgard S., Ciceri P., Wodicka L.M., Pallares G., Hocker M., Treiber D.K., Zarrinkar P.P.a. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2011, 29.
57. Joensuu H., Trent J.C., Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat. Rev. 2011, 37(1):75-88. 10.1016/j.ctrv.2010.04.008.
58. Davis M.I., Hunt J.P., Herrgard S., Ciceri P., Wodicka L.M., Pallares G., Hocker M., Treiber D.K., Zarrinkar P.P. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2011, 29:1046-1051. 10.1038/nbt.1990.
59. S. Rolewski, Clinical review: topical retinoidsy, 2003.
60. Standeven A.M., Johnson A.T., Escobar M., Chandraratna R.A. Specific antagonist of retinoid toxicity in mice. Toxicol. Appl. Pharmacol. 1996, 138(1):169-175. 10.1006/taap.1996.0110.
61. Wolf J. Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv. Ther. 2002, 19(3):109-118. 10.1007/BF02850266.
62. A. Yamamoto, H. Kakuta, H. Miyachi, S. Yukio, Involvement of the retinoid x receptor ligand in the anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in vivo, PPAR Res. 2011 (2011) Article ID 840194. doi:10.1155/2011/840194.
63. Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dandona P. Nuclear factor-?b suppressive and inhibitor-?b stimulatory effects of troglitazone in obese patients with type 2 diabetes. evidence of an antiinflammatory action?. J. Clin. Endocrinol. Metab. 2001, 86(7):3250-3256. 11443197. 10.1210/jcem.86.7.7564.
64. D. Pan, W. Liu, X. Yang, F. Cao, Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury, 2007.
65. H. Rahmani, List of New Predicted Side Effects For Different Drugs. https://www.dropbox.com/s/b99vrgfai3tjaju/NovelSideEffects.html?dl=0.
66. Greenberg D.A., Aminoff M.J., Simon R.P. Headache and Facial Pain 2012, The McGraw-Hill Companies, New York, NY, (Chapter 6). http://mhmedical.com/content.aspx?aid=56671771.
67. 45Ca uptake by rat brain microvesicles. Neurochem. Res. 1994, 19(12):1515-1520. 10.1007/BF00968999.
68. Tfelt-Hansen P., Saxena P.R., Dahlóf C., Pascual J., Láinez M., Henry P., Diener H.-C., Schoenen J., Ferrari M.D., Goadsby P.J. Ergotamine in the acute treatment of migraine. Brain 2000, 123(1):9-18. 10.1093/brain/123.1.9.